Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 16/20 | 0.56 |
| ▸ | PTGS1 | P23219 | 9/20 | 0.56 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.56 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.56 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.56 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.56 |
| ▸ | IDO1 | P14902 | 1/20 | 0.37 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5774670 | 0.87 | PTGS2 (0.64) | PTGS2PTGS1ABCC4ABCB11PDE4D | |
| SCHEMBL24721532 | 0.79 | IDO1 (0.47) | IDO1 | |
| SCHEMBL17878838 | 0.78 | PTGS2 (0.71) | PTGS2PTGS1ABCC4ABCB11PDE4D | |
| SCHEMBL237979 | 0.78 | PTGS2 (0.78) | PTGS2PTGS1ABCC4ABCB11PDE4D | |
| Hydrochloric Acid SCHEMBL4892177 | 0.77 | PTGS2 (0.76) | PTGS2PTGS1ABCC4ABCB11PDE4D | |
| SCHEMBL4027051 | 0.77 | PTGS2 (0.66) | PTGS2PTGS1ABCC4ABCB11PDE4D | |
| SCHEMBL14422875 | 0.76 | PTGS2 (0.67) | PTGS2PTGS1ABCC4ABCB11PDE4D | |
| SCHEMBL5551731 | 0.76 | PTGS2 (0.67) | PTGS2PTGS1ABCC4ABCB11PDE4D | |
| SCHEMBL13114284 | 0.76 | PTGS2 (0.67) | PTGS2PTGS1ABCC4ABCB11PDE4D | |
| SCHEMBL5550637 | 0.74 | PTGS2 (0.61) | PTGS2PTGS1ABCC4ABCB11PDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8841457-B2 | Process for cyclooxygenase-2 selective inhibitor | VIRDEV INTERMEDIATES PVT. LTD. (IN) | 2014-09-23 | — | — | US | claimed |
| US-20130245272-A1 | PROCESS FOR CYCLOOXYGENASE-2 SELECTIVE INHIBITOR | VIRDEV INTERMEDIATES PVT. LTD. (IN) | 2013-09-19 | — | — | US | claimed |
| EP-2649049-B1 | PROCESS TO PRODUCE ETORICOXIB | VIRDEV INTERMEDIATES PVT LTD (IN) | 2016-08-24 | — | — | EP | disclosed |
| US-8841457-B2 | Process for cyclooxygenase-2 selective inhibitor | VIRDEV INTERMEDIATES PVT. LTD. (IN) | 2014-09-23 | — | — | US | disclosed |
| EP-2649049-A2 | PRODUCE TO PRODUCE ETORICOXIB | Virdev Intermediates Pvt. Ltd. (IN) | 2013-10-16 | — | — | EP | disclosed |
| US-20130245272-A1 | PROCESS FOR CYCLOOXYGENASE-2 SELECTIVE INHIBITOR | VIRDEV INTERMEDIATES PVT. LTD. (IN) | 2013-09-19 | — | — | US | disclosed |
| WO-2012066570-A2 | A PROCESS FOR CYCLOOXYGENASE-2 SELECTIVE INHIBITOR | VIRDEV INTERMEDIATES PVT. LTD. (IN) | 2012-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130245272-A1 | PROCESS FOR CYCLOOXYGENASE-2 SELECTIVE INHIBITOR | PTGS2, PTGIS, PTGES2 | PTGS2 1/4885PTGS1 4/4885ABCC4 2658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.